Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14557743 | 0.86 | HRH3 (0.46) | HRH3MEN1NPC1RAB9AKMT2A | |
| SCHEMBL14569599 | 0.79 | EPHX2 (0.48) | MEN1NPC1RAB9AKMT2ADPP4 | |
| SCHEMBL14569506 | 0.79 | ALDH1A1 (0.50) | NPC1RAB9AALDH1A1 | |
| SCHEMBL14610876 | 0.79 | EPHX2 (0.48) | MEN1NPC1RAB9AKMT2ADPP4 | |
| SCHEMBL14569706 | 0.79 | EPHX2 (0.40) | HRH3MEN1NPC1RAB9AKMT2A | |
| SCHEMBL14569600 | 0.78 | DPP4 (0.41) | MEN1NPC1RAB9AKMT2ADPP4 | |
| SCHEMBL14569809 | 0.77 | EPHX2 (0.39) | HRH3MEN1NPC1RAB9AKMT2A | |
| SCHEMBL14569542 | 0.76 | RIPK1 (0.49) | HRH3MEN1KMT2AEPHX2ALDH1A1 | |
| SCHEMBL23236376 | 0.74 | SPHK1 (0.55) | MEN1NPC1RAB9AKMT2ASPHK1 | |
| SCHEMBL23236372 | 0.74 | SPHK1 (0.55) | MEN1NPC1RAB9AKMT2ASPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | HRH3 1894/4885MEN1 3283/4885NPC1 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.